Literature DB >> 27346969

Haemoglobin J-Baltimore can be detected by HbA1c electropherogram but with underestimated HbA1c value.

Valéry Brunel1, Agnčs Lahary2, Abdeslam Chagraoui1, Christian Thuillez3.   

Abstract

Glycated haemoglobin (HbA(1c)) is considered the gold standard for assessing diabetes compensation and treatment. In addition, fortuitous detection of haemoglobin variants during HbA1c measurement is not rare. Recently, two publications reported different conclusions on accuracy of HbA(1c) value using capillary electrophoresis method in presence of haemoglobin J-Baltimore (HbJ).
Here we describe the fortuitous detection of unknown HbJ using capillary electrophoresis for measurement of HbA(1c). A patient followed for gestational diabetes in our laboratory presented unknown haemoglobin on Capillarys 2 Flex Piercing analyser which was identified as HbJ. HbJ is not associated with haematological abnormalities. High Performance Liquid Chromatography methods are known to possibly underestimate HbA(1c) value in the presence of this variant. This variant and its glycated form are clearly distinguished on electropherogram but HbJ was responsible for underestimating the true area of HbA(1c).
 Capillary electrophoresis is a good method for detecting HbJ but does not seem suitable for evaluation of HbA(1C) value in patients in presence of HbJ variant.

Entities:  

Keywords:  capillary electrophoresis; glycated haemoglobin; haemoglobin J-Baltimore

Mesh:

Substances:

Year:  2016        PMID: 27346969      PMCID: PMC4910267          DOI: 10.11613/BM.2016.026

Source DB:  PubMed          Journal:  Biochem Med (Zagreb)        ISSN: 1330-0962            Impact factor:   2.313


Introduction

Glycated haemoglobin (HbA1c) is considered the gold standard for assessing diabetes compensation and treatment. In addition, fortuitous detection of haemoglobin variants during HbA1c measurement is not rare. Recently, an analytical evaluation of Capillarys 2 Flex Piercing (C2FP, Sebia, Lisses, France) has been published, assessing the possible interference of the most common haemoglobin variants in African immigrants to the United States (). The authors concluded that those common African haemoglobin variants, notably heterozygous for haemoglobin S (HbS) or haemoglobin C (HbC), not only could be detected, but also do not interfere with HbA1c results and do not impair the ability of HbA1c to detect abnormal glucose tolerance on C2FP analyser. Although heterozygous for HbS or HbC are the most frequently encountered variants in France they are not the only ones (). In 2013, we introduced C2FP instrument to our clinical biology laboratory at Rouen University Hospital, France to perform HbA1c. Herein we report a case of haemoglobin J-Baltimore detected by electropherogram and discuss the consequences of the presence of this haemoglobin variant on accurate interpretation of HbA1c result obtained by C2FP analyser.

Materials and Methods

A 28-year-old pregnant woman at 29 weeks of amenorrhoea, with no medical history, was referred by her attending physician at our Department of Endocrinology for management of newly diagnosed gestational diabetes. An oral glucose tolerance test and HbA1c measurements were done respectively on Cobas 8000 analyser (Roche, Meylan, France) and C2FP instrument (Sebia, Lisses, France) in our clinical biology laboratory at Rouen University Hospital to monitor her diabetes. Oral glucose tolerance test was performed with 75 g of glucose dissolved in 250 mL of water which was absorbed by the patient.

Results

Fasting glucose, 1 hour and 2 hour levels after glucose charge were measured respectively as 4.8, 10.1 and 8.5 mmol/L. We detected two peaks of unknown haemoglobin on electropherogram. The higher peak was quantified at 47.7%. The other peak, probably corresponding to a glycated form of the first, was quantified at 1.2% (Figure 1). C2FP software does not allow HbA1c calculation because of insufficient separation between the peak of unknown haemoglobin and HbA1c fraction. Therefore, the sample was tested by High Performance Liquid Chromatography (HPLC) Bio-Rad Variant II analyser (BioRad, Marnes-la-Coquette, France). HbA1c was measured at 4.6% (27 mmol/mol) with the presence of an unknown peak in P3 window, the window on Variant’s chromatogram where haemoglobin variant could be detected, quantified at 44.3%. The manufacturer’s instructions define a cut-off in the window as 5% for detection of haemoglobin variant sample. The sample was analysed by the National Haemoglobinopathy Reference Laboratory (Créteil, France) which identified this haemoglobin as J-Baltimore beta 16(A13) Gly>Asp (HbJ). On electropherogram, we clearly observed insufficient separation of HbA1c fraction from HbJ with an underestimation of HbA1c fraction area determined by the C2FP software. We pursued our investigation to measure this interference. Thus, manual off-line recalculation of HbA1c percentage was performed, excluding both unknown peaks. The formula used was %HbA1c = [HbA1c] / ([HbA1c + HbA0]) × 100, then we applied the calibration equation of the software, and the HbA1c value obtained was 4.1% (21 mmol/mol). The laboratory did not communicate this manual off-line recalculation of HbA1c to Department of Endocrinology because of the underestimation of HbA1c was not quantifiable.
Figure 1

Electropherogram from capillary electrophoresis Capillarys 2 Flex Piercing.
Electropherogram with software alarm “atypical profile” presents two peaks of unknown haemoglobins. The higher unknown peak is haemoglobin J-Baltimore (HbJ) and the smaller unknown peak is glycated form of HbJ (HbJ1c). We observe usual fractions of haemoglobin: haemoglobin A (HbA0), A1c (HbA1c), A2 (HbA2). On this electropherogram, we observed insufficient separation of HbA1c fraction from HbJ.

Electropherogram from capillary electrophoresis Capillarys 2 Flex Piercing.
Electropherogram with software alarm “atypical profile” presents two peaks of unknown haemoglobins. The higher unknown peak is haemoglobin J-Baltimore (HbJ) and the smaller unknown peak is glycated form of HbJ (HbJ1c). We observe usual fractions of haemoglobin: haemoglobin A (HbA0), A1c (HbA1c), A2 (HbA2). On this electropherogram, we observed insufficient separation of HbA1c fraction from HbJ.

Discussion

Fortuitous identification of haemoglobin variants during HbA1c measurement is not common and requires screening expertise by the clinical pathologist (). In our laboratory, we perform 12,000 tests for HbA1c measurement per year and we identify approximately 30 cases of haemoglobin variant per year. HbJ was first described in 1963 by Baglioni and Weatherall in a black American family (). Haematological abnormalities are not usually associated with this variant. The analytical impact of this rare variant is well known on HbA1c measurement by HPLC (, ). Only a few recent publications have been published on capillary electrophoresis (CE) methods (, ). Barakat and Roberts explained that the very light load change due to the presence of a glycine in position 16 of the haemoglobin β-chain does not allow clear separation of HbJ or HbJ1c from respectively HbA or HbA1c with HPLC methods and subsequent risk of underestimating HbA1c value (, ). Rhea reported the same results between HPLC method, known with a negative bias, and CE (). Little considered that the HbA1c results of the two samples tested were accurate with CE method (). Here, we clearly observe that we are able to identify the presence of all the fractions of interest of HbA, HbA1c, HbJ and HbJ1c on electropherogram obtained by C2FP analyser. We previously reported that manual off-line recalculation could be useful when CE software does not allow HbA1c calculation (). In conclusion, in this case HbJ was responsible for underestimating the true area of HbA1c, and consequently the proposed manual off-line recalculation of HbA1c value. Although C2FP HbA1c method can detect HbJ variant, the presence of this haemoglobin variant affects the accuracy of C2FP method for HbA1c measurement.
  9 in total

1.  Effects of nine hemoglobin variants on five glycohemoglobin methods.

Authors:  W L Roberts; E L Frank; L Moulton; C Papadea; J K Noffsinger; C N Ou
Journal:  Clin Chem       Date:  2000-04       Impact factor: 8.327

2.  ABNORMAL HUMAN HEMOGLOBINS. IX. CHEMISTRY OF HEMOGLOBIN J-BALTIMORE.

Authors:  C BAGLIONI; D J WEATHERALL
Journal:  Biochim Biophys Acta       Date:  1963-12-13

3.  Neonatal screening for sickle cell disease in France.

Authors:  J Bardakdjian-Michau; M Bahuau; D Hurtrel; C Godart; J Riou; M Mathis; M Goossens; C Badens; R Ducrocq; J Elion; J M Perini
Journal:  J Clin Pathol       Date:  2009-01       Impact factor: 3.411

4.  Falsely low HbA1c value due to a rare variant of hemoglobin J-Baltimore.

Authors:  Ossama Barakat; S T Murali Krishnan; Ketan Dhatariya
Journal:  Prim Care Diabetes       Date:  2008-07-09       Impact factor: 2.459

5.  Fortuitous detection of a case of unknown haemoglobin Athens-Georgia from atypical HbA1c electropherogram.

Authors:  Julien Wils; Patrick Caneiro; Ludivine Lebourg; Agnès Lahary; Abdeslam Chagraoui; Valéry Brunel
Journal:  Clin Chim Acta       Date:  2014-11-05       Impact factor: 3.786

6.  Effects of 49 Different Rare Hb Variants on HbA1c Measurement in Eight Methods.

Authors:  Randie R Little; Sonia L La'ulu; Steven E Hanson; Curt L Rohlfing; Robert L Schmidt
Journal:  J Diabetes Sci Technol       Date:  2015-02-17

7.  Rare presumptive Hb variant misidentification prevents appropriate Hb A1c result.

Authors:  Jeanne M Rhea; Ross Molinaro
Journal:  Clin Chim Acta       Date:  2014-02-07       Impact factor: 3.786

8.  Evaluation of hemoglobin A1c measurement by Capillarys 2 electrophoresis for detection of abnormal glucose tolerance in African immigrants to the United States.

Authors:  Zhen Zhao; Jeffrey Basilio; Steven Hanson; Randie R Little; Anne E Sumner; David B Sacks
Journal:  Clin Chim Acta       Date:  2015-04-08       Impact factor: 3.786

9.  Identification of hemoglobin variants in samples received for glycated hemoglobin testing.

Authors:  Sharon Saw; Tze Ping Loh; Cecilia Yin; Sunil K Sethi
Journal:  Clin Chim Acta       Date:  2012-10-30       Impact factor: 3.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.